Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 565,500 shares, a growth of 46.7% from the September 30th total of 385,600 shares. Based on an average daily trading volume, of 374,200 shares, the days-to-cover ratio is currently 1.5 days. Approximately 12.3% of the company’s shares are sold short.

Virpax Pharmaceuticals Stock Performance

NASDAQ:VRPX traded up $0.06 during trading hours on Monday, reaching $0.68. The company’s stock had a trading volume of 50,216 shares, compared to its average volume of 1,912,556. The stock has a 50 day moving average price of $0.72 and a two-hundred day moving average price of $1.19. Virpax Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $8.00.

Virpax Pharmaceuticals (NASDAQ:VRPX) last announced its earnings results on Monday, August 12th. The company reported ($1.75) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.